GMP pluripotent derivatives

GMP production of pluripotent stem cells and its derivatives (continuation)

The overall goal is to establish pluripotent stem cells (iPS and/or hES cells)
for derivation of GMP approved cells for clinical studies.

Time period: 11/2021 – 11/2023

Lead: Anders Lindahl, Gothenburg University

Involved partners: Gothenburg University, VERIGRAFT AB, Vecura , Takara BIO,
Karolinska Institutet, Lund University, Region Västerbotten

Pluripotent stem cells are the technical foundation for new cell-based therapies as well as research tools for academia and the pharmacological industry. Derivation of iPS cell-lines of GMP grade have been be done in collaboration with partners and is complying with the
regulations as determined by the Swedish MPA (Läkemedelsverket). Robust differentiation protocols have been developed (chondrocytes, Schwann cells). The project part of a lager EU, VR, Vinnova-funded projects.

Work plan:

Establish standardized iPS culture system for all cell- lines
Perform derivation experiments performed including pellet cultures
RNA sequencing of monolayer culture and Bioinformatics
Derivation of Schwann cell protocol
Single cell sequencing of human chondrocytes
Decellularization of nerves from rats
Single cell sequencing of induced chondrocytes from iPS cells

Publications

”Karolinska Institutet Human Embryonic Stem Cell Bank.”